Sponsored Symposium


Sponsored by Sanofi and Drugs for Neglected Diseases initiative (DNDi)

Sheraton - Waterbury (2nd Floor)
Monday, October 29, 7:15 p.m. - 9:15 p.m.

The first all-oral treatment for Trypanosoma brucei gambiense human African trypanosomiasis (g-HAT), co-developed through an innovative public-private partnership between Sanofi and the Drugs for Neglected Diseases initiative (DNDi) has proven to be effective and safe, according to results of clinical trials led by DNDi and numerous partners in DR Congo and Central African Republic, and published in The Lancet in October 2017. This new drug joins new diagnostics to round out the elimination toolbox for this fatal disease that is now at a historical low in terms of global disease burden.

CO-CHAIR
Victor Kande Betu Kuneso
NTD Director, Ministry of Health, Kinshasa, Democratic Republic of the Congo
Luc Kuykens
Senior Vice-President Global Health Programs, Sanofi, Gentilly, France

SESSION INTRODUCTION
Victor Kande Betu Kuneso
NTD Director, Ministry of Health, Kinshasa, Democratic Republic of the Congo

DISCUSSION FACILITATION
Luc Kuykens
Senior Vice President Global Health Programs, Sanofi, Gentilly, France

AN ALTERNATIVE MODEL FOR DRUG DEVELOPMENT: THE STORY OF FEXINIDAZOLE
Nathalie Strub-Wourgaft
Clinical Director, Drugs for Neglected Diseases initiative, Geneva, Switzerland

WORKING IN PARTNERSHIP FOR SLEEPING SICKNESS ELIMINATION: USING NEW TECHNOLOGIES
Erick Mwamba Miaka
Director, National HAT Programme, Kinshasa, Democratic Republic of the Congo

FINDING EVERY LAST CASE: THE ROLE OF DIAGNOSTICS IN HAT ELIMINATION
Veerle Lejon
Research Director, Institut de Recherche pour le Développement, Montpellier, France

ROLL-OUT OF ALL-ORAL TREATMENT: INTRODUCING A DONATION PROGRAM FOR SLEEPING SICKNESS
Luc Kuykens
Senior Vice-President Global Health Programs, Sanofi, Gentilly, France

STRIVING TOWARDS HAT ELIMINATION IN SOUTH SUDAN: AN OPERATIONAL PERSPECTIVE
Laurence Félyaud
Operational Centre Barcelona-Athens, Médecins Sans Frontières

MONITORING HAT ELIMINATION: PLANS FOR VALIDATION
Gerardo Priotto
Department of Control of Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland

Meet us in the TropMed Hub

Visit the TropMed Hub in the Exhibit Hall (Sheraton - Napoleon Ballroom, located near entrance) and visit with representatives from:

- American Committee of Medical Entomology (ACME)
- American Committee of Molecular, Cellular and Immunoparasitology (ACMIP)
- American Committee on Arthropod-Borne Viruses (ACAV)
- American Committee on Clinical Tropical Medicine and Travelers’ Health (ACCTMTH – Clinical Group)
- ASTMH Committee on Global Health (ACGH)
- ASTMH/AJTMH

Our subgroups provide unique forums for members to engage in core scientific, educational, advocacy and policy issues related to a specific expertise with fellow stakeholders of similar interests. Benefits include networking and pre-meeting courses and symposia activities planned for Annual Meetings to enhance career development.

Learn more about:
- What subgroups do
- How to get involved
- The benefits of becoming an ASTMH member
- Submitting material to the American Journal of Tropical Medicine and Hygiene